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Summary
 
Lymphocytes regulate their responsiveness to IL-2 through the transcriptional control of the
IL-2R
 
a
 
 gene, which encodes a component of the high affinity IL-2 receptor. In the mouse IL-2R
 
a
 
gene this control is exerted via two regulatable elements, a promoter proximal region, and an
IL-2–responsive enhancer (IL-2rE) 1.3 kb upstream. In vitro and in vivo functional analysis of
the IL-2rE in the rodent thymic lymphoma-derived, CD4
 
2
 
CD8
 
2
 
 cell line PC60 demonstrated
that three separate elements, sites I, II, and III, were necessary for IL-2 responsiveness; these
three sites demonstrate functional cooperation. Site III contains a consensus binding motif for
members of the Ets family of transcription factors. Here we demonstrate that Elf-1, an Ets-like
protein, binds to site III and participates in IL-2 responsiveness. In vitro site III forms a com-
plex with a protein constitutively present in nuclear extracts from PC60 cells as well as from
normal CD4
 
2
 
CD8
 
2
 
 thymocytes. We have identified this molecule as Elf-1 according to a
number of criteria. The complex possesses an identical electrophoretic mobility to that formed
by recombinant Elf-1 protein and is super-shifted by anti–Elf-1 antibodies. Biotinylated IL-2rE
probes precipitate Elf-1 from PC60 extracts provided site III is intact and both recombinant
and PC60-derived proteins bind with the same relative affinities to different mutants of site III.
In addition, by introducing mutations into the core of the site III Ets-like motif and comparing
the corresponding effects on the in vitro binding of Elf-1 and the in vivo IL-2rE activity, we
provide strong evidence that Elf-1 is directly involved in IL-2 responsiveness. The nature of
the functional cooperativity observed between Elf-1 and the factors binding sites I and II re-
mains unresolved; experiments presented here however suggest that this effect may not require
direct interactions between the proteins binding these three elements.
 
I
 
L-2 is a T cell–derived cytokine implicated in the regula-
tion of growth and differentiation of a variety of cells ex-
pressing IL-2 receptors. The high affinity IL-2 receptor
(IL-2R)
 
1
 
 consists of three distinct subunits, the IL-2R
 
a
 
, -
 
b
 
,
and -
 
g
 
 chains, which are assembled into a signaling com-
plex after their interaction with IL-2 (for reviews see refer-
ences 1–3). Lymphocytes control their level of IL-2 re-
sponsiveness by regulating the expression level of IL-2R.
This is achieved via transcriptional regulation of the IL-2R
 
a
 
gene, and in certain cells the IL-2R
 
b
 
 gene; the IL-2R
 
g
 
subunit is constitutively expressed (4–6). Resting lympho-
cytes do not express the IL-2R
 
a
 
 gene. Transcription of the
gene is induced by signals from the antigen receptor, but in
the absence of any other stimuli, these signals only trigger a
transient wave of IL-2R
 
a
 
 synthesis in T lymphocytes. Max-
imal and sustained IL-2R
 
a
 
 transcription depends on IL-2
itself, which thus acts as a positive feedback regulator of
IL-2R expression and IL-2 responsiveness. The level of
IL-2R
 
a
 
 gene expression is also modulated by other extra-
cellular stimuli, notably IL-1 and TNF (7–9). In CD4
 
2
 
CD8
 
2
 
 thymocytes, IL-1 has a similar effect as antigen in
mature T cells in that it acts synergistically with IL-2 to in-
crease IL-2R
 
a
 
 transcription (6, 10).
 
1
 
Abbreviations used in this paper:
 
 IL-2R, IL-2 receptor; IL-2rE, IL-2–respon-
sive enhancer; PRR, promoter-proximal positive regulatory region; STAT,
signal transducers and activators of transcription.
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The rodent thymic lymphoma-derived cell line PC60
is growth factor independent and resembles early thymic T
cell precursors in that it expresses neither CD4 nor CD8 anti-
gens. This line was the first in which induction of IL-2R
 
a
 
expression by IL-2 was reported (11) and is a well-charac-
terized model system in which to analyze the IL-2 respon-
siveness of this gene (6, 12). As in normal CD4
 
2
 
CD8
 
2
 
 thy-
mocytes, IL-1 and IL-2 act synergistically to induce IL-2R
 
a
 
transcription (9). In a manner similar to antigenic stimula-
tion in mature T cells, in PC60 IL-1 induces only a tran-
sient wave of IL-2R
 
a
 
 expression, and it primes cells to be-
come IL-2 responsive. Transcriptional control of the IL-2R
 
a
 
gene is exerted by two separate regulatory regions in the 5
 
9
 
flanking region, one of which is promoter proximal and re-
quired for IL-1 inducibility and the other a more distal IL-2–
responsive enhancer (IL-2rE) (6). Promoter-proximal posi-
tive regulatory regions (PRRs in the terminology proposed
by John et al. [13]), located between positions 
 
2
 
54 to
 
2
 
584 in the mouse, and 
 
2
 
244 to 
 
2
 
276 (PRRI) and 
 
2
 
137
to 
 
2
 
64 (PRRII) in the human IL-2R
 
a
 
 genes, respectively,
are required for the rapid appearance of IL-2R
 
a
 
 mRNA
after IL-1 exposure of PC60 or EL4 (14) cells, or PMA
treatment of human T cell leukemias (12, 13, 15). Several
DNA-binding factors were implicated in exerting effects on
transcription via these elements, including NF-kB, Elf-1,
and HMG-I(Y) (12–14, 16). Transcriptional stimulation by
IL-2, on the other hand, operates via IL-2rE. The position
of this enhancer in the mouse gene was mapped, by tran-
sient transfection experiments, to a 48-nucleotide stretch,
1.3 kb upstream of the transcriptional start site (12). It cor-
responds to a DNase I hypersensitive site (DH2), that appears
in the chromatin of normal mouse T cells upon stimulation
with Con A and IL-2 (10), and can increase transcription in
response to IL-2 stimulation both in its normal context of
2.5 kb of IL-2R
 
a
 
 5
 
9
 
 flanking region as well as when in-
serted upstream of a non-orthologous promoter. Recently,
the human homologue of the mouse IL-2rE has been
identified in a region 
 
z
 
4 kb upstream of the transcription
start site of the human IL-2R
 
a
 
 gene (17, 18). The mouse
IL-2rE contains three separable 
 
cis
 
-acting elements, named
sites I, II, and III; mutations in any one of these three ele-
ments abolishes IL-2 responsiveness of reporter constructs
containing the IL-2rE, demonstrating functional cooperativ-
ity between the sites (12) (see Fig. 1 
 
A
 
 for summary). By
identifying the proteins which bind to these DNA elements
it will be possible to characterize the nature of some of the
downstream transducers of the IL-2 signaling pathway.
Sites I and II of the IL-2rE contain sequence elements
potentially recognized by signal transducers and activators
of transcription (STAT) proteins (19), some of which have
recently been shown to be activated by IL-2 (20, 21). In
PC60, IL-2rE function most likely also depends on the
binding of IL-2 activated STAT5 to both sites I and II
(Meyer, M., P. Reichenbach, V. Schindler, E. Soldaini, M.
Nabholz, manuscript submitted for publication). Site III
contains a consensus binding site for members of the Ets-
like family of transcription factors, distinguished by a con-
served DNA binding domain which recognizes sequences
containing a GGAA/T core (22). Ets-like proteins have
been shown to be involved in the regulation of genes im-
portant for several different biological processes including
lymphocyte differentiation, T cell activation, growth con-
trol, viral infection cycles, and transformation (22). Ets-like
proteins often interact with other transcription factors and
accessory proteins forming complexes both in the presence
and absence of DNA (23–27).
The aim of this study is to elucidate which, if any, of the
Ets-like proteins bind to site III and form part of the com-
plex of proteins generating the response of the IL-2R
 
a
 
gene to IL-2. Using several experimental approaches, we
demonstrate that site III specifically binds the Elf-1 tran-
scription factor. A direct correlation between the effect of
site III point mutations on Elf-1 binding in vitro and on the
in vivo activity of the corresponding IL-2rE forms, strongly
implies Elf-1 as the transcription factor involved in the IL-2
inducibility of the IL-2R
 
a
 
 gene. Experiments designed to
elucidate the molecular basis of the cooperativity observed
between the three sites making up the IL-2rE suggest that
this phenomenon does not rely on the formation of direct
interactions between Elf-1 and the factors binding to sites I
and II. 
 
Materials and Methods
 
Cells and Culture Conditions.
 
The PC60.21.14 cell line, fur-
ther referred to as PC60, and its culture conditions have been de-
scribed previously (9, 28, 29). Human recombinant interleukins
were the kind gifts of Glaxo IMB S.A. (Geneva, Switzerland).
IL-1
 
b
 
, further referred to as IL-1, was used at final concentrations
of 1 ng/ml; IL-2 was used at 100 units/ml. Spleenic T cells were
prepared by fractionation on nylon wool columns according to
 
Current Protocols in Immunology
 
 (30). CD4
 
2
 
CD8
 
2
 
 thymocytes
were prepared and cultured as described previously (31). The pu-
rity of CD4
 
2
 
CD8
 
2
 
 thymocytes, determined by flow cytometry,
was 98%.
 
Plasmids and Preparation of Mutant Constructs.
 
The reference plas-
mid for transient transfection experiments, pG
 
b
 
Ac
 
b
 
G1D, the
wild-type IL-2R
 
a
 
/reporter construct, pwt1
 
b
 
G1, in which the
segment from nt 
 
2
 
2539 to 
 
1
 
93 of the IL-2R
 
a
 
 5
 
9
 
 flanking region
is fused to a 
 
b
 
-globin reporter gene, and the mutants used for the
experiments described in Fig. 1, 
 
B
 
 and 
 
D
 
 have been described
previously (12, 32). Mutations within the IL-2rE sequence were
introduced into the pwt1
 
b
 
G1 plasmid using the Chameleon Mu-
tagenesis Kit (Stratagene, Zürich, Switzerland). Plasmids were
prepared using Qiagen Plasmid kits, and the validity of all the
constructs was confirmed by DNA sequencing using a T7 poly-
merase sequencing kit (Amersham Rahn, Zürich, Switzerland).
 
Transfection of PC60 Cells and Reporter Gene Assays.
 
PC60 cells
were cultured in the presence of IL-1 for 3 d and then transiently
transfected with DNA constructs using the DEAE-dextran
method (33). Each transfection included a defined ratio between
the reference plasmid and a IL-2R
 
a
 
/reporter construct. After trans-
fection, cells were split into two equal aliquots. One aliquot was
grown for an additional two days in the presence of IL-1 and
IL-2, while the other was cultured in the presence of IL-1 alone.
The transcripts from the IL-2R
 
a
 
/reporter gene and from the ref-
erence plasmid were then measured by RT PCR as described
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previously (12, 32). Results from this assay were quantified using
a PhosphorImager and ImageQuant software (Molecular Dynamics,
Sunny Vale, CA). Signals due to the IL-2R
 
a
 
/reporter gene con-
structs were normalized by comparing them to signals generated
from the reference plasmid. To determine the level of IL-2 in-
duction, transcriptional activity generated from the reporter con-
struct in the presence of both IL-1 and IL-2 was divided by the
activity observed in cells cultured in the presence of IL-1 alone. 
 
Electrophoretic Mobility Shift Assays (Bandshifts).
 
Nuclear extracts
were prepared essentially as described by Schreiber et al. (34): 1 
 
3
 
10
 
6
 
 cells were rinsed in PBS and lysed in 200 
 
m
 
l of buffer A (10
mM Hepes, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM
EGTA, 1 mM DTT, 2% NP-40). The lysate was centrifuged, the
supernatant discarded, and the proteins extracted from the nuclear
pellet in buffer B (high salt buffer: 20 mM Hepes, pH 7.9, 0.4 M
KCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT). Both buffers A
and B contained protease (1 
 
m
 
g/ml aprotinin, 1 
 
m
 
g/ml leupeptin,
1 mM PMSF) and phosphatase inhibitors (10 mM NaF, 1 mM
Na
 
3
 
VO
 
3
 
). Binding reactions were performed in a final volume of
20 
 
m
 
l in binding buffer (10 mM Tris, pH 7.5, 100 mM KCl, 10%
glycerol, 1 mM DTT, 1 
 
m
 
g/ml BSA, 1 
 
m
 
g dIdC, 0.5 
 
m
 
g soni-
cated salmon sperm DNA) containing 1 
 
m
 
g of cell nuclear extract
or 1 
 
m
 
g of recombinant protein, 1 
 
3
 
 10
 
6
 
 cpm of an end-labeled
PCR fragment (spanning bases 
 
2
 
1384 to 
 
2
 
1290 of the 5
 
9
 
 flank-
ing region of the IL-2R
 
a
 
 gene, Fig. 1 
 
B
 
) or SIII oligonucleotide
probe (see Table 1). Reactions were incubated on ice for 20 min
and then separated on 4.5% non-denaturing polyacrylamide gels
in 0.3
 
3
 
 TBE. For competition experiments, unlabeled PCR
fragments or oligonucleotides were premixed with the radiola-
beled probe before the addition of the proteins; for antibody su-
pershift experiments the antibodies were preincubated with the
nuclear proteins for the specified time before the addition of the
radiolabeled probe.
Oligonucleotides (see Table 1) were obtained from MWG-
Biotech (Ebersberg, Germany) or Microsynth (Balgach, Switzer-
land). Annealed oligonucleotides were stored in 10 mM Tris, pH
7.5, 50 mM NaCl. As a nonspecific competitor for band shift as-
says, a double-stranded oligonucleotide with the sequence 5
 
9
 
-
AGAGTTAGCTTGCGGTTCCCAGG-3
 
9
 
 was used.
 
DNaseI Footprint Analysis.
 
The probe for in vitro footprinting
assays was obtained by subcloning the 188-bp SauIIIA–HindII frag-
ment of the IL-2R
 
a
 
 59 flanking region into Sma I–BamHI–
digested pUC18. To label the non-coding strand this plasmid was
linearized with EcoRI and the resulting sticky end filled in with a
nucleotide mixture containing [32P]ATP. After digestion with
PstI the labeled IL-2Ra fragment was purified on a non-denatur-
ing 8% polyacrylamide gel and recovered by electroelution. For
each footprint reaction 2 ng of probe and, where indicated, a
100-fold excess of competitor was incubated with 35 mg of nu-
clear extract in 27 ml of buffer (33 mM Hepes, pH 6, 0.1 mM
EDTA, 50 mM KCl, 0.6 mM DTT, 4 mM MgCl2, 0.4 mM 2-ME,
0.1 mg/ml poly-dIdC, containing several protease inhibitors, listed
above) for 30 min on ice. The samples were prewarmed for 1 min
at 208C and 0.1 unit of Dnase I (Pharmacia, Duebendorf, Swit-
zerland) in 2 ml 25 mM CaCl2 and 10 mM Hepes, pH 7.6, was
added. After 1 min at 208C the reaction was stopped and the DNA
extracted, denatured, and fractionated on a 6% sequencing gel.
Recombinant Proteins and Antibodies. Recombinant AcNPV bac-
uloviruses expressing rElf-1 and rEts-1 proteins (35, 36), and anti–
Ets-1/2 (no. 8 [37]), anti–Pu-1 (no. 65 [38]) and anti–Fli-1 (no.
61 [39]) antisera have been described previously. Anti–Elf-1 poly-
clonal antibodies (C-20) were purchased from Santa Cruz Bio-
technology (CA), and HRP-coupled goat anti–rabbit antibodies
from Biorad Laboratories (CA).
Affinity Precipitation of IL-2rE–bound Proteins. Biotinylated IL-2rE
probes were obtained as follows: (a) wild type and probes carry-
ing mutations that abolish the activity of a single enhancer site
were made by amplifying the corresponding reporter plasmid
(M4 for site I, M9 for site II, M12 for III, see Table 1 and refer-
ence 12 for sequences) with primers spanning the segment be-
tween nucleotides 21402 (oligonucleotide A) and 21286 (bioti-
nylated oligonucleotide B) of the IL-2Ra 59 flanking region. (b)
Probes in which more than one site was inactivated were ob-
tained in three steps essentially as described in Ho et al. (40) and
explained here for the example of a probe in which all three en-
hancer sites are destroyed. (i) The plasmid carrying the mutation
in site I (M4) was amplified with oligonucleotide A and a 39 oli-
gonucleotide C9, covering site II with the changes destroying this
site. Simultaneously the plasmid with a mutation in site III (M12)
was amplified with a 59 primer (C) complementary to oligonucle-
otide C9 and oligonucleotide B. (ii) The resulting PCR products
were gel-purified, denatured, and annealed with each other. (c) The
annealing mixture was used as template for an extension reaction,
and the resulting full-length IL-2rE fragments amplified with
primers A and B. PCR fragments were purified and quantified by
densitometric analysis of the corresponding bands on agarose gels. 
IL-2rE–binding proteins recovered from whole PC60 cell ex-
tracts were isolated after lysis of 2.0 3 106 cells/ml in buffer C
(50 mM Tris-HCl, pH 8.0, 0.5% NP-40, 150 mM NaCl, 0.1
mM EDTA, 10 mM NaF, 1 mM Na3VO3, 1 mM PMSF, 1 mM
DTT, 1 mg/ml aprotinin, 1 mg/ml leupeptin). Aliquots of extract
from 2.0 3 106 cells were incubated with 1 mg biotinylated probe
in buffer C at 48C for 1 h. The probe and proteins bound were
recovered by incubation with 30 ml streptavidin-agarose beads
(Sigma Chemie, Buchs, Switzerland). Beads were washed twice
in buffer C and then boiled in gel loading buffer (2% SDS, 10%
glycerol, 80 mM Tris-HCl, pH 6.8, 0.01% bromophenol blue,
5% 2-mercaptoethanol). Eluted proteins were separated by SDS-
PAGE on 10% gels and transferred to Immobilon-P membranes
(Millipore, Volketswil, Switzerland). Elf-1–specific bands were
revealed with a 1/500 dilution of anti–Elf-1 antibody by ECL
(according to the manufacturer’s instructions, Amersham Rahn,
Zürich, Switzerland).
Results and Discussion
Site III of the Mouse IL-2rE Forms an In Vitro Complex with
at Least One Specific Protein. To identify the proteins that
Table 1. IL-2rE Mutants
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bind to the IL-2rE, and may therefore be implicated in the
regulation of IL-2rE activity, we performed bandshift assays
with a probe containing the entire IL-2Ra enhancer (nu-
cleotides 21384 to 21290). This probe forms a number of
complexes with proteins extracted from IL-1–primed and
IL-2–induced PC60 nuclei (Fig. 1 B). To determine which
of these complexes is due to specific DNA-binding pro-
teins recognizing functionally important sites within the
IL-2rE, we used a DNA competition-based assay. In this
assay DNA fragments harboring specific mutations defining
the sites required for IL-2rE enhancer activity are used as
competitors to disrupt the formation of the IL-2rE com-
plexes (Fig. 1 B). Three of the IL-2rE complexes were in-
hibited by the addition of an excess of unlabeled DNA, but
only the complex with the lowest mobility (complex 1) re-
sults from an interaction with a protein specifically binding
a discrete region of the IL-2rE. Mutations M12 and M13
strongly impair the capacity of the corresponding DNA
fragments to compete for the formation of this specific
complex. The flanking mutations M11 and M14 result in a
relatively lower, but still significant, reduction in the com-
petitive efficiency of the IL-2rE DNA. M12 and M13
abolish IL-2rE activity and define site III; the striking cor-
relation of this in vivo effect with the effect on competitor
efficiency in vitro suggests that the specific bandshift com-
plex is due to one or several proteins participating in the
control of the IL-2rE activity.
On a probe spanning the entire IL-2rE (nucleotides
21472 to 21268), PC60 extracts produce a specific foot-
print extending from the 59 end of site III to several bases
downstream, essentially covering the Ets-like protein con-
sensus binding motif (Fig. 1 C, lanes 2 and 3). Detection of
this footprint is abolished by the addition of unlabeled probe
(Fig. 1 C, lanes 1 and 4). The protein complex that gives
rise to the footprint is present in nuclear extracts from both
unstimulated and IL-1–primed and IL-2–stimulated cells
(compare Fig. 1 C, lanes 2 and 3). The same is true for the
protein(s) forming the site III–specific complex detected in
bandshift assays (data not shown). (Note that under the
conditions used here we could not detect PC60 proteins
binding specifically to site I or II. However, using other
techniques we have shown that IL-2–induced STAT5 pro-
teins bind to these sites but not to site III [Meyer, M., P. Reich-
enbach, V. Schindler, E. Soldaini, M. Nabholz, manuscript
submitted for publication].)
SIII, a shorter IL-2rE probe spanning nucleotides 21336
to 21302, contains all the necessary sequence information
to allow the formation of the site III–specific complex with
extracts from PC60 (Fig. 1 D) or normal CD42CD82 thy-
mocytes (Fig. 1 E). The single, specific SIII complex dem-
onstrates the same sensitivity to mutant IL-2rE fragments in
competition assays as that of the complete IL-2rE probe–
site III–specific complex (compare Fig. 1, B, D, and E). 
The Ets-like Transcription Factor Elf-1 Is Present in the Site
III–specific Complex. Site III contains a consensus binding
sequence for members of the Ets-like family of transcrip-
tion factors. The two mutations, M12 and M13, which de-
fine site III and abolish competition for the site III–specific
complex, destroy this consensus binding site. Mutation M14,
which has no significant effect on enhancer activity and re-
duces competition in band shifts only to a minor extent
(compare Fig. 1, A and B), results in a sequence that can
still bind some Ets-like proteins. To determine which, if any,
of the numerous Ets family members participates in the for-
mation of the site III–specific bandshift complex several ap-
proaches were employed.
First, using recombinant Elf-1, an Ets-like protein, and
Ets-1 itself in bandshift assays, we found that Elf-1 forms a
complex with the SIII probe that migrates with a mobility
identical to that of the complex generated in PC60 ex-
tracts. Recombinant Ets-1 binds to the SIII probe but re-
sults in the formation of a faster migrating complex (Fig. 2 A).
The observation that the complex generated by PC60 nuclear
extracts comigrates with that formed by recombinant Elf-1
suggests that there is no requirement for additional proteins.
Second, we tested the capacity of antibodies raised
against the Ets-like proteins Elf-1, Ets-1/2, Fli-1 (Fig. 2, B
and C) and Pu-1 to affect the mobility of the site III–spe-
cific bandshift complex. The anti–Elf-1 antibodies super-
shifted the complex formed by non-induced, as well as
primed and IL-2 induced nuclear extracts from PC60 (Fig.
2, B and C; the appearance of the additional nonspecific
Figure 1. Identification of a DNA-binding protein that recognizes a critical element in the IL-2rE of the mouse IL-2Ra gene. A shows a summary of
the published results (12) of the functional analysis of the mouse IL-2rE. The histogram shows the effect of mutations in the IL-2rE on the IL-2 inducibil-
ity of constructs containing 2.5 kb of the IL-2Ra 59 flanking region. Mutations are either substitutions (M) or deletions (D) (see Table 1). The presence
of the three separate elements, site I, II, and III, in the enhancer is required for IL-2 responsiveness. The Ets-like consensus site that overlaps with site III
and the STAT consensus binding motifs in sites I and II are underlined. (B). Bandshift competition analysis of the complexes formed between a probe
containing the entire IL-2rE (nucleotides 21384 to 21290) and nuclear extracts isolated from IL-1–primed, IL-2–induced PC60 cells. The competitors
are unlabeled IL-2rE fragments used at a 200-fold molar excess which contain the mutations indicated in A. Competitors containing the mutations defin-
ing site III do not compete for the formation of complex 1 which is marked with a filled arrowhead. Empty arrowheads point to complexes 2 and 3,
which are competed by all competitors. F, free probe. (C) DNase I footprint analysis of the IL-2rE in vitro. DNase I protection analysis of the IL-2rE
was performed with nuclear extracts isolated from either untreated or IL-1–primed and IL-2–induced PC60 cells as indicated. The reactions were per-
formed either in the presence or absence of unlabeled IL-2rE probe (wt) as detailed. The positions of the three sites (sites I, II and III) delineated in A
were determined by fractionating a sequencing reaction on the same gel (data not shown). (D and E) A site III probe (SIII) is sufficient to allow formation
of the IL-2rE–specific complex corresponding to complex 1 in B from PC60 (D) and CD42CD82 thymocytes (E). The radiolabeled probe SIII spanning
nucleotides 21336 to 21302 of the IL-2rE forms a specific complex, indicated with a filled arrowhead, with nuclear extracts isolated from IL-1–primed,
IL-2–induced PC60 cells. The SIII-specific complex was subjected to competition analysis with the following unlabeled probes: SIII, unlabeled SIII; NS,
a nonspecific oligonucleotide of the same length as SIII; C1, a mutant form of SIII (see Table 1) which contains a mutation in the core of the Ets-like
binding site; M9 to M15, mutant forms of the IL-2rE (see A and Table 1).
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higher mobility bands in Fig. 2 B results from incubation at
room temperature. These bands are not present when the
incubations are performed on ice as in Fig. 2 C) or with
CD42CD82 thymocytes (Fig. 2 D). The observation that
the proportions of the complexes supershifted varies be-
tween experiments suggests that the anti–Elf-1 antiserum
only partially supershifts the site III specific complex as a
result of the relatively low affinity of this reagent. Anti–Elf-
1 antibodies also supershift the site III specific complex
formed with the complete IL-2rE probe (data not shown).
Antibodies against Ets-1 and Ets-2, Fli-1 (Fig. 2 C), and
Pu-1 (data not shown) do not affect the mobility of the site
III–specific complex.
Third, the nature of the protein(s) which could be pre-
cipitated from PC60-derived nuclear extracts by biotiny-
lated IL-2rE oligonucleotide probes was investigated. IL-2rE
probes containing all three sites precipitate a protein recog-
nized by the anti–Elf-1 antiserum and whose molecular
mass, 91 kD, corresponds to that of Elf-1 (Fig. 3 A). The Elf-1
doublet observed on Western blots has been reported pre-
viously (41), and the relative levels of the two protein spe-
cies remain unchanged after IL-1 priming or IL-2 induction
(data not shown). As expected from the bandshift experi-
ments, the presence in PC60 nuclei of Elf-1 active for
DNA binding does not depend on IL-2 stimulation, al-
though sometimes a small increase is seen in extracts from
IL-2–treated cells (Fig. 3, A and C). Experiments with bio-
tinylated IL-2rE probes containing mutations in sites I, II,
or III clearly show that Elf-1 binding to IL-2rE is abolished
by a mutation in site III, whereas mutations in sites I or II
have no effect on the amount of Elf-1 protein precipitated
(Fig. 3, B and C). The human IL-2rE contains an addi-
tional Ets-like protein-binding site overlapping a STAT
consensus binding motif in site I (17, 18). Fig. 3 B demon-
strates that the murine site I does not bind Elf-1, in agree-
ment with the inability of site I to compete for the site III–
specific complex (Fig. 1 B). Transfection experiments in
human lymphoid cell lines suggest that Elf-1 binding to site I
may produce a negative effect on the activity of the IL-2rE
enhancer (17). If this effect is important in the regulation of
the human IL-2Ra gene expression in normal lympho-
cytes, it suggests the presence of subtle differences in the
transcriptional control of the homologous mouse and hu-
man genes.
Finally, we compared the effect of point mutations in the
core of the site III Ets-like consensus site both on the abil-
ity of recombinant Elf-1 to bind and on the formation of the
site III–specific complex by PC60 extracts. Binding site se-
lection studies have identified the consensus sequences rec-
ognized by human and mouse Elf-1 as being A(A/t)(C/a)
CCGGAAGT(A/S) (42) and A(A/T)(A/c)CCGGAAGT
(G/T)(G/A) (3) respectively. Both contain the core GGAA
(underlined) characteristic of Ets-like binding sites; site III
of the IL-2rE (AATCAGGAAGTTG (in italics nucle-
otides identical in all three motifs) is very similar to these
sequences. There is complete concordance in the behavior
Figure 2. Elf-1 generates the IL-2rE site III–specific complex in vitro. A shows a comparison of the relative electrophoretic mobilities of the site III–
specific complexes formed by recombinant Ets-1 (rEts-1), Elf-1 (rElf-1), and IL-1–primed, IL-2–induced PC60 nuclear extracts (PC60) and the SIII probe.
The complexes formed by the recombinant proteins and PC60 extracts are indicated with empty and filled arrowheads, respectively. F, unbound probe. (B,
C, and D). The effect of antibodies against different Ets-like proteins on the electrophoretic mobility of the site III–specific complex. The SIII probe was
incubated with nuclear extracts from PC60 cells (B, C) or from unfractionated or CD42CD82 thymocytes (D), in the presence or absence of antibodies
against Elf-1, Ets-1/2 or Fli-1 as indicated. PC60 cells were either untreated, IL-1 primed alone, or IL-1 primed and IL-2 induced as indicated.
CD42CD82 thymocytes were either freshly isolated or stimulated for 2 d with PMA, ionomycin, IL-1, and IL-2. Filled and empty arrowheads mark the
site III–specific complex in the presence or absence of antibodies, respectively. In B binding reactions were performed at room temperature, whereas in
C and D incubations were performed on ice. 1 ml and 2.5 ml of the anti–Elf-1 antibodies was used to produce the supershift visible in B and C, respec-
tively. B illustrates that the site III–specific supershifted complex is competed by the SIII probe itself (SIII) but not by a nonspecific competitor (NS) or by
a probe containing a mutation in the site III Ets core (C1, see Table 1 and Fig. 1 D). F, Unbound probe.
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of recombinant Elf-1–derived and PC60-derived Elf-1 site
III complexes in terms of their sensitivities to the various mu-
tations present within the core sequence (Fig. 4, A and B).
Note, in particular, the effect of the change GGAA to GGAT
(mutant C5), which is not expected to affect binding of
Ets-1 but does, as previously described (35, 42), result in a
strong reduction of the binding of recombinant Elf-1 as
well as of the site III–binding protein in PC60 extracts.
The Effects of Site III Mutations On Elf-1 Binding In Vitro
Correlate with Those on IL-2rR Activity In Vivo. The data pre-
sented above demonstrate that the protein in PC60 extracts
binding to site III of the IL-2rE is Elf-1. Although previous
mutational analyses suggest that Elf-1 is required for IL-2rE
inducibility, they do not rule out the possibility that an-
other protein, not detectable in in vitro binding experi-
ments, is responsible for site III function in vivo. To obtain
further evidence that Elf-1 is indeed the protein upon
which site III function depends in vivo, we compared the
effect of mutations in the core of the Elf-1 binding site on
the in vivo IL-2 responsiveness of the IL-2rE. This was
measured using an accurate PCR-based reporter assay de-
scribed previously (12, 32). Comparison of the results ob-
tained from these assays (Fig. 5) with those obtained in the
bandshift competition experiments (Fig. 4, A and B) shows
good agreement between these two parameters. Mutations
C1 and C3 very strongly affect Elf-1 binding in vitro and
reduce the IL-2 responsiveness of the IL-2rE about fivefold.
Mutations C2 and C4 result in a slightly weaker effect on
both Elf-1 binding and IL-2rE activity, and mutation C5,
which competes for Elf-1 binding more strongly than the
other core mutants, reduces enhancer inducibility twofold.
As mentioned above this mutation reduces the binding of
Elf-1 but should have little effect on the binding of Ets-1 or
Ets-2. This change therefore results in a core element still
recognized by Elf-1 but at a much reduced efficiency. Two
additional mutations, S1 and S2, which alter the nucle-
otides flanking the Ets-like core sequence, almost com-
pletely abolish IL-2rE activity. Note that S2 overlaps with
M14 which itself has little effect on Elf-1 binding and en-
hancer inducibility. Together these data lend strong support
to the hypothesis that Elf-1 participates in the IL-2 response
of the mouse IL-2rE. In the recently identified human IL-
2rE the individual sites required for enhancer activity, in-
Figure 3. Elf-1 is precipitated from PC60–derived nuclear extracts by
biotinylated IL-2rE oligonucleotide probes containing an intact site III.
The ability of various biotinylated IL-2rE oligonucleotide probes to pre-
cipitate Elf-1 from PC60-derived nuclear extracts was investigated. The
nature of the IL-2rE probe used to precipitate the protein is indicated be-
low the lane(s); a blank or crossed box, respectively, serves to illustrate the
presence of either a wild-type or a mutant sequence at the designated site
of the IL-2rE enhancer (the mutant forms of sites I, II, and III contain the
sequences M4, M9, and M12, respectively, which destroy IL-2rE en-
hancer activity, see Fig. 1 A and Table 1). In A and C nuclear extracts
were prepared from cells that had been IL-1 primed and then IL-2 in-
duced for the specified time periods. In B, all extracts were prepared from
cells that had been IL-1 primed and IL-2 induced for 30 min. The blots
were probed with anti–Elf-1 antibodies and molecular mass markers are
indicated.
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cluding site III, are conserved (17, 18), and John et al. (18)
has provided evidence suggesting that the human gene is
also regulated by Elf-1.
There is evidence implicating Elf-1 in the regulation of a
number of lymphocyte specific genes (IL-2 [43], GM-CSF
[24], CD4 [41], IL-3 [23], IgH39 [44] and terminal trans-
ferase [45]). The case of the IL-2Ra gene is interesting as
this gene contains two (or, in man, three) Elf-1 sites, form-
ing part of both the promoter proximal and distal control
elements. Elf-1 DNA-binding activity in PC60 cells is not
affected by IL-2 (Fig. 3 A). Thus, the simplest model for
the molecular basis of the IL-2rE’s IL-2 inducibility is that
enhancer activity depends on the binding of other IL-2–acti-
vated proteins (most likely STAT5 [Meyer, W., P. Reichen-
bach, V. Schindler, E. Soldaini, M. Nabholz, manuscript sub-
mitted for publication]) to sites I and II and that Elf-1
remains constitutively present on site III. Constitutive bind-
ing of Elf-1 to regulatory elements implicated in stimula-
tion of transcription has been described previously in studies
of the PHA and PMA inducible IL-3 gene (23). Experi-
ments to detect possible posttranslational modifications of
Elf-1 controlling its capacity to contribute to enhancer ac-
tivity have so far been unsuccessful. Elf-1 activity may also
depend on interactions with other inducible factors binding
in its immediate vicinity. In this context it is interesting
that mutations M11 and D15 flanking the Elf-1 binding site
result in a moderate reduction of IL-2rE activity; these re-
gions contain potential binding sites for NFIL-6 and AP-1.
Note, however, that the site III specific complex formed
by PC60 extracts has the same electrophoretic mobility as
that formed with recombinant Elf-1, indicating that the
PC60 complex does not contain additional proteins.
The Nature of the Functional Cooperativity between the Three
Sites Making Up the IL-2rE Remains Unresolved. One of the
striking features resulting from the study of the mouse IL-2rE
is that mutations in any one of the three sites that make up
this enhancer abrogate IL-2 responsiveness. The observa-
tion that the distances between the three IL-2rE sites (z20
nucleotides or two helical turns from center to center) are
conserved between mouse and man suggests that evolu-
tionary conservation of the relative orientations of proteins
binding to them is important, possibly because of a require-
ment for direct interactions between the factors binding to
the three sites. However, the insertion of five nucleotides
in mutant I5, which changes the relative orientation of site
III with respect to sites I and II, results in only a minor ef-
Figure 4. A comparison of the sensitivity of the PC60 nuclear extract and recombinant Elf-1–derived site III–specific complexes to different competi-
tors. IL-1–primed, IL-2–induced PC60 nuclear extracts (PC60 NE, A) or recombinant Elf-1 proteins (rElf-1, B) and the SIII probe were incubated in the
presence or absence of the indicated unlabeled competitors: SIII, C1 to C5, see Table 1. The SIII competitor was added at a 50-, 150-, 500-, and 1,500-
fold molar excess to the labeled SIII as illustrated by the increasing gradients, the other competitors were used at a 1,500-fold molar excess. The final
DNA concentrations of all the reactions were adjusted by addition of an appropriate amount nonspecific competitor (NS, see Table 1). The site III–spe-
cific complex is highlighted with a filled arrowhead; two nonspecific complexes (NS) formed in incubations with the recombinant Elf-1 protein are indi-
cated with empty arrowheads. Lane 12 contains the site III complex formed by either recombinant Elf-1 (A) or PC60 extracts (B) in order to allow com-
parison of their relative mobilities. F, Unbound probe.
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Figure 5. The effects of different site III mutations on the IL-2 inducibility of
IL-2rE. The effects of site III mutants on the activity of the IL-2rE were investi-
gated in transiently transfected PC60 cells. 2.5 kb of the mouse IL-2Ra gene 59
flanking region, containing either the wild-type or the indicated mutant form of
the IL-2rE (see Table 1), was fused to the rabbit b-globin gene. These plasmids
were transiently transfected into IL-1–primed PC60 cells together with a refer-
ence plasmid (for details see reference 12). The transfected cells were either cul-
tured in IL-1 alone or with IL-1 and IL-2. 2 d later the relative amounts of re-
porter gene mRNA were measured and the IL-2 response of each plasmid
determined (see Materials and Methods). For each IL-2rE mutation, with the ex-
ception of C1, the assay was repeated with at least two independently derived
mutants and in every instance the assay was performed twice with all constructs.
IL-2 responses are plotted as percent of the response of the wild-type construct in
the same experiment. Wild-type responses varied from 5.2- to 8.0-fold induc-
tion. For each mutant the mean response 6 SD is given. Shading of the histo-
gram bars distinguishes different classes of mutations: (black) mutations in the Elf-1
core motif; (gray) mutations flanking the core motif; (diagonally hatched) 5 nucle-
otide insertion between sites II and III.
The simplest model consistent with our findings is that
the different IL-2rE binding proteins cooperate by interact-
ing independently with components of the transcription ini-
tiation complex, as has been described previously in in vi-
tro studies of transcriptional regulation by the Drosophila
proteins Bicoid and Hunchback (46) and in the control of
the c-fos gene (47). But our data do not rule out more
complex models involving additional proteins or cofactors
needed for an efficient stimulation of transcription by the
IL-2rE.
fect on IL-2 inducibility, arguing against direct protein–
protein interactions (Fig. 5). Using biotinylated IL-2rE oli-
gonucleotide probes, we demonstrated that the presence or
absence of sites I and II has no affect on the amount of Elf-1
protein precipitated from PC60-derived nuclear extracts
(Fig. 3 C; probing the same membranes with anti-STAT5
antiserum reveals that STAT5 binds to site I and II [Reichen-
bach, P., manuscript in preparation]) again arguing against
direct protein–protein interactions. However, this possibil-
ity needs to be explored further using additional approaches.
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